Table 2.
Comparison among the standard and modified EGFR PharmDx™ and higy-sensitivity immunostaining for EGFR using DAK-H1-WT and Novolink
| Intensity score | Standard EGFR PharmDx™ | Modified EGFR PharmDx™ | High-sensitivity immunostaining | |||
|---|---|---|---|---|---|---|
|
| ||||||
| Non-neoplastic crypt epithelial cells | Colorectal cancer cells | Non-neoplastic crypt epithelial cells | Colorectal cancer cells | Non-neoplastic crypt epithelial cells | Colorectal cancer cells | |
| 0 | 3 (10%) | 14 (47%) | 0 (0) | 0 (0) | 0 (0) | 0 (0) |
| 1+ | 23 (77%) | 6 (20%) | 0 (0) | 0 (0) | 0 (0) | 0 (0) |
| 2+ | 3 (10%) | 6 (20%) | 2 (7%) | 2 (7%) | 2 (7%) | 2 (7%) |
| 3+ | 1 (3%) | 4 (13%) | 28 (93%) | 28 (93%) | 28 (93%) | 28 (93%) |
0: negative, 1+: weak intensity, 2+: moderate intensity, 3+: strong intensity.